Leader
Is there a future for extracorporeal photochemotherapy in the treatment of the rheumatological diseases?
| The first 150 words of the full text of this article appear below. |
| |
Introduction |
|---|
The list of so called `disease modifying agents' in rheumatoid arthritis now includes methotrexate and cyclosporin A. The efficacy of certain speculative treatments in the rheumatic diseases including antibody based therapies such as anti-tumour necrosis factor1 and anti-ICAM,2 cytokine toxic fusion proteins,3 oral administration of antigens,4 stem cell therapy,5 and cytokine receptor antagonists6 are being investigated. After the reported success of extracorporeal photochemotherapy (ECP) in systemically disseminated cutaneous T cell lymphoma7 in 1987 its benefits are also being explored in rheumatological conditions.
| |
Technique of ECP |
|---|
Two hours after oral methoxypsoralen, blood is removed from the
patient, exposed to ultraviolet A light at room temperature, and then
reinfused. This procedure can either be done as a continuous flow or by
concentrating the lymphocytes and reinfusing as a bolus, and is usually
performed on two consecutive days each month. In the initial group of
37 patients with therapy resistant cutaneous T cell lymphoma 27 improved with ECP, and over
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
